Patents by Inventor Masha Fridkis-Hareli
Masha Fridkis-Hareli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230414732Abstract: Embedded Epitope Random Peptides (EERP) for the treatment of autoimmune diseases are provided. Each EERP is a polypeptide consisting of a random sequence of three or more amino acids in a specific molar ratio, within which is embedded an epitope composed of a specific amino acid sequence. Also provided is a method of treating an autoimmune disease or condition using the EERP.Type: ApplicationFiled: November 8, 2021Publication date: December 28, 2023Applicant: PALENA THERAPEUTICS, INC.Inventor: Masha FRIDKIS-HARELI
-
Patent number: 9066905Abstract: The invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.Type: GrantFiled: January 9, 2008Date of Patent: June 30, 2015Assignee: President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Patent number: 9028835Abstract: Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. The random copolymers have amino acids alanine, lysine and one or more of the hydrophobic amino acids valine, phenylalanine, tryptophan and tyrosine. Random three-amino acid copolymer FAK efficiently suppressed EAE induced in SJL/J (H-2S) mice with the encephalitogenic epitope PLP 139-151. Random four-amino acid copolymers VYAK and tryptophan-containing VWAK were efficacious in alleviating severity and duration of symptoms of EAE induced by MBP 85-99 (SEQ ID NO:2), in a humanized mouse model expressing genes for both an HLA-DR-2 linked to multiple sclerosis (MS) in humans and for a T cell receptor from an MS patient.Type: GrantFiled: July 12, 2011Date of Patent: May 12, 2015Assignee: President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Publication number: 20150030560Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.Type: ApplicationFiled: February 24, 2014Publication date: January 29, 2015Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: Rina Aharoni, Dvora Teitelbaum, Ruth Arnon, Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger
-
Publication number: 20110286959Abstract: Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. Fifty-mers of FEAK were effective inhibitors of MBP 85-99- or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones. These copolymers efficiently suppressed the mouse disease EAE, which was induced in a susceptible SJL/J (H-2s) strain of mice with either whole spinal cord homogenate (WSCH) or with the encephalitogenic epitope PLP 139-151 (SEQ ID NO:4). YFAK 50-mer having a molar ratio of about Y 0.8:F 0.2 inhibited binding of biotinylated MBP 85-99 epitope to HLA-DR-2 molecules more efficiently than either unlabeled MBP 85-99 or Copaxone®. YFAK and FAK copolymers efficiently suppressed EAE induced in SJL/J (H-2S) mice with the encephalitogenic epitope PLP 139-151.Type: ApplicationFiled: July 12, 2011Publication date: November 24, 2011Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Patent number: 8017125Abstract: Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. Fifty-mers of FEAK were effective inhibitors of MBP 85-99- or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones. These copolymers efficiently suppressed the mouse disease EAE, which was induced in a susceptible SJL/J (H-2s) strain of mice with either whole spinal cord homogenate (WSCH) or with the encephalitogenic epitope PLP 139-151 (SEQ ID NO:4). YFAK 50-mer having a molar ratio of about Y 0.8:F 0.2 inhibited binding of biotinylated MBP 85-99 epitope to HLA-DR-2 molecules more efficiently than either unlabeled MBP 85-99 or Copaxone®. YFAK and FAK copolymers efficiently suppressed EAE induced in SJL/J (H-2S) mice with the encephalitogenic epitope PLP 139-151.Type: GrantFiled: December 26, 2007Date of Patent: September 13, 2011Assignee: President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Publication number: 20100298227Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.Type: ApplicationFiled: August 29, 2008Publication date: November 25, 2010Inventors: Rina Aharoni, Dvora Teitelbaum, Ruth Arnon, Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger
-
Patent number: 7566767Abstract: The invention provides peptide compositions, and methods of making and using therapeutic compositions for treatment of a subject for an autoimmune or an inflammatory disease. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.Type: GrantFiled: May 15, 2003Date of Patent: July 28, 2009Assignee: President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Patent number: 7456252Abstract: The invention provides peptide compositions and methods of making and using therapeutic compositions comprising peptides for the treatment of a subject having a demyelinating condition.Type: GrantFiled: June 10, 2005Date of Patent: November 25, 2008Assignee: President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Publication number: 20080241099Abstract: Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. Fifty-mers of FEAK were effective inhibitors of MBP 85-99- or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones. These copolymers efficiently suppressed the mouse disease EAE, which was induced in a susceptible SJL/J (H-2s) strain of mice with either whole spinal cord homogenate (WSCH) or with the encephalitogenic epitope PLP 139-151 (SEQ ID NO:4). YFAK 50-mer having a molar ratio of about Y 0.8:F 0.2 inhibited binding of biotinylated MBP 85-99 epitope to HLA-DR-2 molecules more efficiently than either unlabeled MBP 85-99 or Copaxone®. YFAK and FAK copolymers efficiently suppressed EAE induced in SJL/J (H-2s) mice with the encephalitogenic epitope PLP 139-151.Type: ApplicationFiled: December 26, 2007Publication date: October 2, 2008Inventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Patent number: 7425332Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.Type: GrantFiled: September 27, 2006Date of Patent: September 16, 2008Assignees: Yeda Research and Development Co., Ltd., President and Fellows of Harvard UniversityInventors: Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger, Rina Aharoni, Dvora Teitelbaum, Ruth Arnon
-
Publication number: 20080207526Abstract: The invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.Type: ApplicationFiled: January 9, 2008Publication date: August 28, 2008Inventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Patent number: 7381790Abstract: Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. Fifty-mers of FEAK were effective inhibitors of MBP 85-99- or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones. These copolymers efficiently suppressed the mouse disease EAE, which was induced in a susceptible SJL/J (H-2S) strain of mice with either whole spinal cord homogenate (WSCH) or with the encephalitogenic epitope PLP 139-151 (SEQ ID NO:4). YFAK 50-mer having a molar ratio of about Y 0.8:F 0.2 inhibited binding of biotinylated MBP 85-99 epitope to HLA-DR-2 molecules more efficiently than either unlabeled MBP 85-99 or Copaxone®. YFAK and FAK copolymers efficiently suppressed EAE induced in SJL/J (H-2S) mice with the encephalitogenic epitope PLP 139-151.Type: GrantFiled: April 3, 2003Date of Patent: June 3, 2008Assignee: President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Patent number: 7279172Abstract: The present invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.Type: GrantFiled: January 23, 2001Date of Patent: October 9, 2007Assignees: Yeda Research and Development Co., Ltd., President and Fellows of Harvard CollegeInventors: Rina Aharoni, Dvora Teitelbaum, Ruth Arnon, Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger
-
Publication number: 20070021341Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.Type: ApplicationFiled: September 27, 2006Publication date: January 25, 2007Inventors: Michael Sela, Masha Fridkis-Hareli, Jack Strominger, Rina Aharoni, Dvora Teitelbaum, Ruth Arnon
-
Publication number: 20060020109Abstract: The invention provides peptide compositions and methods of making and using therapeutic compositions comprising peptides for the treatment of a subject having a demyelinating condition.Type: ApplicationFiled: June 10, 2005Publication date: January 26, 2006Inventors: Jack Strominger, Masha Fridkis-Hareli
-
Patent number: 6930168Abstract: The invention provides peptide compositions and methods of making and using therapeutic compositions comprising peptides for the treatment of a subject having a demyelinating condition.Type: GrantFiled: January 24, 2002Date of Patent: August 16, 2005Assignee: The President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Publication number: 20040038887Abstract: Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. Fifty-mers of FEAK were effective inhibitors of MBP 85-99- or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones. These copolymers efficiently suppressed the mouse disease EAE, which was induced in a susceptible SJL/J (H-2S) strain of mice with either whole spinal cord homogenate (WSCH) or with the encephalitogenic epitope PLP 139-151 (SEQ ID NO:4). YFAK 50-mer having a molar ratio of about Y 0.8:F 0.2 inhibited binding of biotinylated MBP 85-99 epitope to HLA-DR-2 molecules more efficiently than either unlabeled MBP 85-99 or Copaxone®. YFAK and FAK copolymers efficiently suppressed EAE induced in SJL/J (H-2S) mice with the encephalitogenic epitope PLP 139-151.Type: ApplicationFiled: April 3, 2003Publication date: February 26, 2004Inventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Publication number: 20040006022Abstract: The invention provides peptide compositions, and methods of making and using therapeutic compositions for treatment of a subject for an autoimmune or an inflammatory disease. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.Type: ApplicationFiled: May 15, 2003Publication date: January 8, 2004Applicant: President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Publication number: 20030064915Abstract: The invention provides peptide compositions and methods of making and using therapeutic compositions comprising peptides for the treatment of a subject having a demyelinating condition.Type: ApplicationFiled: January 24, 2002Publication date: April 3, 2003Inventors: Jack L. Strominger, Masha Fridkis-Hareli